Terns Pharmaceuticals Inc to Discuss the TERN-701 Data Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ritu Baral - Cowen and Company LLC - Analyst : Hi guys, thanks for taking the question. Congrats on today's data and reception at ASH How are you guys thinking about further interrogating the Semblix resistant population going forward even before the phase 3? You had one. Call amendment, would you consider looking at pocket mutation patients and other sort of harder to treat patients? I'm trying to get my head around, how a PKI binding mutation would then confer resistance to a stamp inhibitor, which implies, there's a lot about these mutations that are not understood and could better elucidate the value opportunity of 701.

Question: Ritu Baral - Cowen and Company LLC - Analyst : Fair enough. And is there anything in the data as presented today that suggests to you that you may need to pick one dose, or are you really thinking about moving both doses forward in the phase 3?

Question: Graig Suvannavejh - Mizuho Securities USA LLC - Analyst : Hey, it's Graig. Thanks for taking my questions and, congrats again on the data. I just wanted to focus on deep molecular responses. I think, many of us have been focused, much more on the six-month MMR. Can you just, perhaps for us, put into context how important, that, number that you reported is? I think you had a slide in the beginning or somewhere in the deck where you compare versus others, but, could you just, elaborate more on that, please?

Question: Graig Suvannavejh - Mizuho Securities USA LLC - Analyst : Thanks for that. And then just maybe a follow-up just on timelines. I know one of the, milestones or catalysts that you're pointing out for 2026 is getting feedback from the FDA and, I guess sign off on whatever a pivotal, program, might look like. While it may be too early to speculate now, but, is it reasonable to assume that the earliest you could start those studies would probably be in 2027, or is there a potential chance that you might be able to start, in 2026?

Question: Graig Suvannavejh - Mizuho Securities USA LLC - Analyst : Okay, Thank you and again, congrats on that tremendous data set today at ASH. LSEG STREETEVENTS | www.lseg.com | Contact Us consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies.

Question: Silvan Tuerkcan - Citizens JMP Securities LLC - Analyst : Yeah, thank you for taking my questions and congratulations on the great update here. Maybe just, I want to focus a little bit on the high baseline transcript patients where about half of your patients get a 2 log or better improvement. What is it about TERN-701 that can drive down, the, these levels in these patients so rapidly and so profoundly?

Question: Silvan Tuerkcan - Citizens JMP Securities LLC - Analyst : Great, thank you. And maybe on the numbers that you presented of Asciminib being discontinued due to intolerability, do you have any sense already? I mean, you only have one patient discontinue and and that was not due to drug, but when do you think, will you be in a position to say or see if your profile has an impact on discontinuation rates due to the drug?

Question: Silvan Tuerkcan - Citizens JMP Securities LLC - Analyst : Great, thank you and congrats.

Question: Corinne Johnson - Goldman Sachs Group Inc - Analyst : Good afternoon. I'm curious. I think a lot of questions have been asked and answered already, but you spoke to the translation from phase 1 to phase 3 data with respect to achieved MMR and the other key endpoints. But as you think about moving into further, like frontline and second line patient populations, how should we think about kind of the translation of clinical response data as you get into those earlier line settings? Thanks.

Question: Srikripa Devarakonda - Suntrust Robinson Humphrey Capital Markets - Analyst : Hey guys, congrats on the data, and thank you for, taking my question. So, when you think about target population and sequencing. For the first round, what do you expect the earliest adoption, is it in post SMMF failures, Asciminib intolerant, and without a head-to-head trial versus Asciminib, what's the best way to frame value for payers. And then just to follow-up, the enrollment velocity has been fantastic. You noted, Amy, that the enrollment surpassed 85 patients. Wondering, which geographies or sites are contributing most, or is it just the data that you stored that helped, with acceleration of the enrollment? Thank you.

Question: Srikripa Devarakonda - Suntrust Robinson Humphrey Capital Markets - Analyst : Thank you. Congrats again.